BAY-293 is another SOS1 inhibitor that was shown to exhibit activity against KRASG12C-mutant cell lines in combination with ARS-853, a KRASG12C inhibitor.255 BAY-293 has also demonstrated cytotoxicity against other KRAS-mutant NSCLC and PDAC cell lines and synergy with MEK, CDK4/6, topoisomerase I, or EGFR inhibitors.256. This evidence concerns the gene KRAS and non-small cell lung carcinoma.